EC Number   |
Specific Activity Minimum [µmol/min/mg] |
Specific Activity Maximum [µmol/min/mg] |
Reference |
|---|
   3.4.17.20 | -999 |
- |
- |
28942, 28943, 653008 |
| 3.4.17.20 | -999 |
- |
assay development and optimization, overview |
670058 |
| 3.4.17.20 | -999 |
- |
binding capacity of recombinant wild-type and chimeric mutant isozymes to fibrinogen and plasminogen, overview |
652560 |
| 3.4.17.20 | -999 |
- |
coupled assay methods, overview |
668287 |
| 3.4.17.20 | -999 |
- |
develpoment of a fast kinetic assay for plasma enzyme quantification, coupled assay with pyruvate kinase/lactate dehydrogenase in microtiter plates, reaction scheme overview |
670060 |
| 3.4.17.20 | -999 |
- |
electroluminescence assay. The high sensitivity of the assay allows the determination of the activatable levels of TAFI in human and other animal plasma in presence of epsilon-aminocaproic acid, an active-site inhibitor that stabilizes TAFIa |
649320 |
| 3.4.17.20 | -999 |
- |
enzyme plasma concentration of healthy male persons, correlation of enzyme plasma concentration to cardiovascular diseases, overview |
670940 |
| 3.4.17.20 | -999 |
- |
hemodynamics in untreated hearts of dogs and hearts treated with enzyme inhibitor MERGETPA and/or plasminogen activator, overview |
670947 |
| 3.4.17.20 | -999 |
- |
in vivo arteriovenous shunt thrombosis model, ex vivo clot lysis assay |
653008 |
| 3.4.17.20 | -999 |
- |
plasminogen and fibrinogen binding activity of the enzyme |
670059 |
